MorphoSys AG

Industry · 11 registered clinical trials.

Status	Trial	Phase	Started
Completed	Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL Diffuse Large B Cell Lymphoma	—	2020-04-01
Completed	Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Ad Diffuse Large B-cell Lymphoma	Phase 1	2019-12-11
Completed	Lenalidomide Monotherapy in R/R DLBCL Diffuse Large B Cell Lymphoma	—	2019-04-12
Completed	Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 2	2016-11-01
Completed	Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Diffuse Large B-cell Lymphoma	Phase 2	2016-03-29
Completed	Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) Non-Hodgkin Lymphoma	Phase 2	2013-04-23
Terminated	Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) Acute Lymphoblastic Leukemia	Phase 2	2013-04-01
Completed	Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis Multiple Sclerosis	Phase 1 / Phase 2	2012-01-01
Completed	A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma Multiple Myeloma	Phase 1 / Phase 2	2011-07-01
Completed	Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis Rheumatoid Arthritis	Phase 1 / Phase 2	2009-12-01
Approved For Marketing	Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL DLBCL	—	—